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We recently uncovered a regulatory pathway of the muscle
isoform of glycogen phosphorylase (PYGM) that plays an impor-
tant role in regulating immune function in T cells. Here, using
various enzymatic, pulldown, and immunoprecipitation assays,
we describe signaling cross-talk between the small GTPases
RAS and RAP1A, member of RAS oncogene family (RAP1)
in human Kit 225 lymphoid cells, which, in turn, is regulated by
the epidermal growth factor receptor (EGFR). We found that
this communication bridge is essential for glycogen phos-
phorylase (PYG) activation through the canonical pathway
because this enzyme is inactive in the absence of adenylyl
cyclase type 6 (ADCY6). PYG activation required stimulation
of both exchange protein directly activated by cAMP 2
(EPAC2) and RAP1 via RAS and ADCY6 phosphorylation,
with the latter being mediated by Raf-1 proto-oncogene, Ser/
Thr kinase (RAF1). Consistent with this model, PYG activa-
tion was EGFR-dependent and may be initiated by the consti-
tutively active form of RAS. Consequently, PYG activation in
Kit 225 T cells could be blocked with specific inhibitors of
RAS, EPAC, RAP1, RAF1, ADCY6, and cAMP-dependent
protein kinase. Our results establish a new paradigm for the
mechanism of PYG activation, which depends on the type of
receptor involved.
Glycogen phosphorylase (PYG,6 EC 2.4.1.1) catalyzes and
regulates the breakdown of glycogen (glycogenolysis) from its
intracellular stores to release glucose 1-phosphate. In mam-
mals, PYG exists in three different isoforms, each encoded by a
different gene: brain (PYGB), liver (PYGL), and muscle (PYGM)
(1). Recently, we and others reported that PYGM is also
expressed in T lymphocytes (2, 3), where it plays a crucial role in
the control of interleukin (IL)-2–stimulated T-cell migration
and proliferation (3–5). PYG activation occurs in an isoform-
dependent manner; activation can be regulated by reversible
serine 14 phosphorylation (PGYL), or by both serine 14 phos-
phorylation and allosteric modification (PYGB and PYGM)
(6 –9). Both mechanisms are mediated through the control of
adenylyl cyclase activity (7, 9), converting ATP to cAMP, a key
second messenger in eukaryotic intracellular signaling (6, 10).
cAMP mediates myriad cellular functions by acting on effec-
tor molecules, such as EPAC, a guanine nucleotide exchange
factor (GEF) (11), and cAMP-dependent protein kinases
(PKAs) (11, 12), which leads to the phosphorylation of PYG at
serine 14 (7). In addition, hydrolysis of ATP generates AMP
(13), which can mediate PYG activation by allosteric modifica-
tion (8, 10). Against this background, we have previously
reported that the transition of PYGM from the inactive to the
active state in IL-2–stimulated T lymphocytes occurs by allo-
steric modifications that are dependent on the small GTPase
RAC1 (RAS-related C3 botulinum toxin substrate 1) and inde-
pendent from the adenylyl cyclase (ADCY)/cAMP pathway.
Mechanistically, RAC1 binds to the RAC-binding domain of
PYGM (amino acids 191–270), which is adjacent to the AMP-
binding site (3).
Small GTPases of the RAS superfamily are key players in the
complex signaling networks that control cellular physiology
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(14 –17). They are positively regulated by signals from a large
number of membrane receptors, including G protein-coupled
receptors (16, 17), T-cell antigen receptor (18, 19), B-cell recep-
tor (20, 21), IL-2 receptor (IL-2R) (3), and platelet-derived
growth factor or epidermal growth factor receptor (EGFR) (16,
17, 22, 23). Small GTPases function as molecular switches that
cycle between an inactive and an active GTP-bound state, with
the transition between each state regulated by GEFs. In their
active configuration, GTPases interact with downstream effec-
tor molecules to promote numerous biological responses (16,
24). There are a great variety of GTPase effector molecules,
such as kinases (including RAF-1 prot-oncogene) (22, 23),
PYGM (3), and also GEFs such as RAS-guanyl-releasing protein
1 (19, 21), T-cell lymphoma invasion and metastasis-inducing
protein 1, 2 (TIAM1, TIAM2) (25, 26) or cAMP-regulated
GEFII (EPAC2) (27).
Regarding EGFR, it has been well-established that it is
expressed on many different hematopoietic cell types, includ-
ing macrophages (28, 29), monocytes (30), and plasma cells
(31), and also in both T-helper-2 (32) and CD4 (33) cells. Of
special relevance is its expression in T-helper-2 cells,
because EGFR participates in the control of innate immune
response at the site of inflammation (32). In this context,
using Kit 225 T cells, a human T cell line established from a
patient with T cell chronic lymphocytic leukemia (34), we
show here that subsequent to EGFR stimulation, RAS coop-
erates with RAP1 to activate PYG. By combining pharmaco-
logical and genetic approaches, we identify EPAC2 as the
bridge between RAS and RAP1. We also show that cross-talk
between these two small GTPases regulates PYG activity
through ADCY6. Overall, these results reveal an unantici-
pated relationship between small GTPases of the RAS family
(RAS and RAP1) and glycogen metabolism through PYG.
Interestingly, we demonstrate that, depending on the stim-
ulus (IL-2 or EGF), lymphoid cells will use one signaling
pathway over the other to direct different cellular responses,
but both lead to activation of PYG.
Results
EPAC–RAP1 mediates PYG activation
To examine whether EPAC could mediate PYG activation, T
cells were deprived of IL-2 for 48 h and were then stimulated or
not for 10 min with 10 M 8-pCPT-2-O-Me-cAMP, a potent
and selective activator of EPAC (35). Cells were then lysed,
and PYG activity was determined as described under “Exper-
imental procedures.” The EPAC activator induced robust
PYG activity in T cells, which was similar to that induced by
IL-2 (Fig. 1A). To test whether engagement of EPAC stimu-
lated RAP1 activation, we repeated EPAC activation in
T-cells and measured RAP1 activation using a pulldown
assay. A substantial increase in the active form of RAP1
(RAP1-GTP) was observed following 10 min of 8-pCPT-2-
O-Me-cAMP treatment (Fig. 1B).
To examine the putative association between RAP1 and PYG
activation, T-cells were transiently transfected with either an
empty vector (mock control) or cDNAs encoding WT RAP1 or
the constitutively active form of RAP1 (RAP1Q63E) for 24 h,
and PYG activity was examined as before. Transfection of
RAP1Q63E, but not WT RAP1, activated PYG to a level compa-
rable with that obtained with IL-2 stimulation (Fig. 1C), sug-
gesting that the potent stimulating effect of RAP1Q63E was
specific to its active configuration. Western blotting showed
that WT RAP1 and RAP1Q63E were equally expressed in T
cells (Fig. 1C).
We next used an ADCY inhibitor, MDL12330A (36), to
determine whether some ADCY activity is needed for the
EPAC–RAP1 signaling complex to control PYG pathway acti-
vation. Accordingly, T cells were pretreated or not with 10 M
MDL12330A, followed by stimulation with 10 M forskolin or
8-pCPT-2-O-Me-cAMP for 10 min before measurement of
PYG activity. Both forskolin and 8-pCPT-2-O-Me-cAMP
induced robust PYG activity, which depended on ADCY (Fig.
1D). The result obtained with forskolin in the presence of the
ADCY inhibitor was expected, because there is a direct rela-
tionship between forskolin and ADCY activation. It was, how-
ever, surprising that the ADCY inhibitor blocked EPAC action
on PYG, suggesting that ADCY is situated between EPAC and
PYG.
To test the aforementioned hypothesis, IL-2– deprived T
cells were transfected as before with WT or RAP1Q63E. After
24 h, cells were pretreated with either 10 M MDL12330A or
vehicle (0.1% DMSO) for 1 h, followed by stimulation or not
with 10 M forskolin for 10 min, and PYG activity was sub-
sequently measured. As shown in Fig. 2A, RAP1Q63E induced
PYG activity to a level comparable with that induced by for-
skolin. As expected, MDL12330A efficiently inhibited fors-
kolin-stimulated PYG activity. MDL12330A also completely
blocked PYG activity induced by RAP1Q63E (Fig. 2A). West-
ern blotting confirmed that RAP1Q63E expression was equiv-
alent under both conditions. Overall, these results suggest
that the EPAC–RAP1 signaling axis regulates PYG activation
via ADCY.
Beazely et al. (37) have previously reported that RAF1 kinase
mediates phosphorylation and activation of ADCY6. To test
the hypothesis that EPAC and RAP1 mediate PYG activation
via the RAF1 kinase/ADCY6 pathway, we transfected IL-2–
deprived T cells with RAP1Q63E or a control vector for 24 h,
after which cells were pretreated with either 10 M GW5074 (a
RAF1 kinase inhibitor) (38) or vehicle (0.1% DMSO) for 1 h.
Cells were then stimulated or not with 10 M 8-pCPT-2-O-
Me-cAMP for 10 min, and PYG activity was measured. Both
8-pCPT-2-O-Me-cAMP and RAP1Q63E induced PYG activity
to a comparable level (Fig. 2B). GW5074 efficiently blocked
PYG activity stimulated by 8-pCPT-2-O-Me-cAMP and
RAP1Q63E overexpression (Fig. 2B). Western blotting con-
firmed that RAP1Q63E expression was equivalent under both
conditions.
To monitor the status of the EPAC–RAP1 pathway in this
signaling cascade, we analyzed the levels of phosphorylated
RAF1 and ERK1/2 during EPAC stimulation by Western
blotting using phospho-specific antibodies to RAF1 and
ERK1/2. As shown in Fig. 3A, T cells responded to EPAC
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stimulation by phosphorylating RAF1 and ERK1/2 upon
8-pCPT-2-O-Me-cAMP treatment. These results indicate
that the EPAC–RAP pathway regulates RAF1/ERK1/2 phos-
phorylation in T cells.
This result prompted us to test whether ADCY6 could link
PYG to RAF1 in the EPAC–RAP1 signaling pathway. To this
end, T cells overexpressing FLAG-ADCY6 were pretreated or
not with 10 M GW5074 for 1 h, after which they were stimu-
lated with 10 M 8-pCPT-2-O-Me-cAMP for 10 min. Cells
were then lysed, and cell lysates were immunoprecipitated as
described under “Experimental procedures.” Results showed
that 8-pCPT-2-O-Me-cAMP induced ADCY6 serine phos-
Figure 1. EPAC–RAP1 proteins stimulate glycogen phosphorylase activation in Kit 225 T cells. Cells deprived of IL-2 for 48 h were stimulated () or not
() (A and B) with 500 units ml1 IL-2 (A) or 10 M 8-pCPT-2-O-Me-cAMP (A and B) for 10 min and lysed. Cell lysates were used to measure glycogen
phosphorylase activity (A) and RAP1 activation (B) by an affinity precipitation assay using the GST-RBD of RalGDS. Precipitated active RAP1 (RAP1-GTP) and total
RAP1 from cell lysates were analyzed by Western blotting using a specific anti-RAP1 antibody. Results are representative of five independent experiments. C,
cells deprived of IL-2 for 24 h were transfected with plasmids coding for pMT2-HA (mock control), pMT2-HA-RAP1, and pMT2-HA-RAP1Q63E. At 24 h post-
transfection, cells were stimulated or not with 500 units ml1 IL-2 for 10 min and lysed. Cell extracts were used to measure glycogen phosphorylase activity.
Western blot analysis of protein expression levels was carried out using a specific anti-HA antibody. D, cells deprived of IL-2 for 48 h were treated with an
adenylyl cyclase inhibitor (10 M MDL12330A) or vehicle (0.1% DMSO) for 1 h and then treated or not with 10 M forskolin or 10 M 8-pCPT-2-O-Me-cAMP for
10 min and lysed. Cell extracts were used to measure glycogen phosphorylase activity. Results presented as histograms show the mean  S.D. (error bars) of
four (A), five (C), and three (D) independent experiments performed in triplicates. ***, p  0.001. B, box plots; each box includes values from five different
samples. All values are expressed in arbitrary units. Differences between unstimulated and stimulated states were p  0.0062 (##) in all cases (Mann–Whitney
test).
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phorylation; however, this did not occur in the presence of
GW5074 (Fig. 3B, top, lane 4). Equal levels of ADCY6 expres-
sion in T-transfected cells and -tubulin were verified by West-
ern blotting (Fig. 3B, second and third panels).
Next, to verify whether the absence of ADCY6 serine phos-
phorylation results in a blockade of cAMP generation, T cells
were pretreated or not with 10 M GW5074 for 1 h and there-
after stimulated with 10 M 8-pCPT-2-O-Me-cAMP for 10
min before measurement of cAMP generation. Cells were
then lysed, and cAMP was determined as described under
“Experimental procedures.” Results showed that 8-pCPT-2-O-
Me-cAMP induced cAMP generation; however, GW5074 pre-
vented cAMP accumulation induced by 8-pCPT-2-O-Me-
cAMP (Fig. 3C).
Epidermal growth factor receptor mediates PYG activation in
Kit 225 T cells
We previously showed that IL-2–mediated PYGM activation
in T cells depends on RAC1 and is independent of PKA (3),
whereas EGF-mediated stimulation of RAF1 potentiates ADCY6
activation in intact cells (37). Thus, we examined the effect of
different growth factors on PYG activation in T cells. Cells were
deprived of IL-2 for 48 h and were then stimulated or not with
10 ng ml1 EGF, 50 g ml1 fibroblast growth factor (FGF), 20
ng ml1 PDGF, or 10 ng ml1 vascular endothelial growth fac-
tor (VEGF) for 10 min. PYG activity was then measured in cell
lysates. As shown in Fig. 4A, only EGF stimulated PYG activity
in T cells.
Given this result, we investigated the potential role of EGFR
in the regulation of PYG activity via the RAF1/ADCY6 signaling
pathway. T cells were deprived of IL-2 for 48 h and were then
pretreated with 10 M GW5074, 10 M MDL12330A, or vehicle
(0.1% DMSO) for 1 h, followed by stimulation or not with 10 ng
ml1 EGF or 500 units ml1 IL-2 for 10 min before measure-
ment of PYG activity. As expected, neither ADCY inhibition
(MDL12330A) nor RAF1 inhibition (GW5074) blocked IL-2–
mediated PYG activation (Fig. 4B, gray bars). By contrast, both
inhibitors strongly blocked EGFR-mediated PYG activation
(Fig. 4B, closed bars). Taken together, these results suggest that
EGFR-mediated PYG activation requires the involvement of
RAF1 and ADCY6.
To verify the involvement of EGFR and also to examine the
potential role of PKA in this signaling pathway, T cells were
deprived of IL-2 for 48 h and were then pretreated with an
EGFR inhibitor (GW2974, 10 M) (39), PKA inhibitors (H-89
(10 M) and Rp-cAMPS (10 M)), or vehicle (0.1% DMSO) for
1 h, followed by stimulation with 10 ng ml1 EGF for 10 min
and measurement of PYG activity. EGFR tyrosine kinase inhi-
bition with GW2974 strongly blocked EGFR-mediated PYG
activity in T cells, and a similar result was found in cells pre-
treated either with H-89 or Rp-cAMPS (Fig. 4C). To test
whether RAP1 activation depends on EGFR, IL-2– deprived T
cells were pretreated with 10 M GW2974 or vehicle (0.1%
DMSO), followed or not by stimulation with 10 ng ml1 EGF
for 10 min, and RAP1 activation was subsequently measured
by a pulldown assay. Control stimulated cells exhibited both
robust RAP1 activation (Fig. 5A, first panel, lane 2) and RAF1
and ERK1/2 phosphorylation (Fig. 5A, third and fourth panels).
By contrast, GW2974 efficiently blocked EGFR-mediated
RAP1 activation and also RAF1 and ERK1/2 phosphorylation
(Fig. 5A, lanes 3 and 4 of the first, third, and fourth panels).
Equal levels of RAP1 and -tubulin expression were verified by
Western blotting (Fig. 5A, second and fifth panels). Overall, the
Figure 2. RAP1 mediates glycogen phosphorylase activation via adenylyl cyclase. T cells deprived of IL-2 for 48 h were pretreated with an adenylyl cyclase
inhibitor (10 M MDL12330A) () (A), a RAF1 inhibitor (10 M GW5074) () (B), or vehicle (0.1% DMSO) () (A and B) for 1 h and stimulated () or not () with
10 M forskolin (A) or 10 M 8-pCPT-2-O-Me-cAMP (B) for 10 min and lysed. Cell extracts were used to measure glycogen phosphorylase activity. The results (A
and B) show the mean  S.D. (error bars) of three independent experiments performed in triplicates. ***, p  0.001.
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results indicate that EGF-stimulated cells control RAP1, RAF1,
and ERK1/2 activation, and EGFR is required for ADCY6 and
PKA to mediate PYG activation.
To determine whether RAP1 is located, up- or downstream
of ADCY6 in the signaling pathway originating from EGFR for
PYG activation, we used endoribonuclease-prepared siRNA
(esiRNA) and transient transfection to knock down ADCY6
expression in T cells. Thus, cells were transfected with an
esiRNA targeting human ADCY6 or an esiRNA targeting en-
hanced GFP (EGFP), as a negative control. At 24 h post-trans-
fection, the active endogenous RAP1 was measured by a pull-
down assay in T cells stimulated or not with EGF for 10 min. As
shown in Fig. 5B, EGF stimulated robust RAP1 activation in
EGFP (esiRNA)-transfected T cells. Conversely, RAP1 activa-
tion was unaffected in ADCY6-knockdown cells stimulated
with EGF for 10 min. Western blotting confirmed the loss of
expression of ADCY6 expression after esiRNA transfection
(Fig. 5B). These results indicate that RAP1 is located upstream
of ADCY6.
To confirm that ADCY6 functions as a PYG-activating mol-
ecule in T cells, we repeated ADCY6 silencing and measured
EGF-stimulated PYG activity. The results showed that EGF was
unable to stimulate PYG activation in the absence of ADCY6
expression (Fig. 6A). In addition, the absence of ADCY6 expres-
sion prevented EGF-mediated cAMP generation (Fig. 6B).
Epidermal growth factor receptor is linked to glycogen
phosphorylase via the RAS–EPAC2–RAP1 signaling pathway
To investigate whether EPAC participates in EGF-stimulated
PYG activation, T cells were deprived of IL-2 for 48 h and were
then pretreated with either 10 M ESI-09, a specific and potent
inhibitor of EPAC (40, 41), or vehicle (0.1% DMSO) for 1 h and
then stimulated or not with 10 M 8-pCPT-2-O-Me-cAMP or
10 ng ml1 EGF for 10 min, followed by measurement of PYG
Figure 3. RAF1 connects the GTPase RAP1 and adenylyl cyclase 6. A, T cells deprived of IL-2 for 48 h were stimulated () or not () with 10 M 8-pCPT-2-
O-Me-cAMP for 10 min and lysed. Cell lysates were used to measure the levels of activated RAF1 and ERK1/2 and total loaded protein using anti-phospho-RAF1,
anti-RAF1, anti-phospho-ERK1/2, and anti-ERK1/2 by Western blotting. Results are representative of four independent experiments. B, T cells deprived of IL-2
for 24 h were transfected with the pMT2-FLAG-ADCY6 vector. At 24 h post-transfection, cells were pretreated with the RAF1 inhibitor (10 M) or vehicle (0.1%
DMSO) for 1 h. Subsequently, the cells were stimulated or not with 10 M 8-pCPT-2-O-Me-cAMP for 10 min and lysed. Cell lysates were immunoprecipitated
with an anti-FLAG antibody, and the immunoreactive bands were visualized using anti-phosphoserine (pS) and anti-FLAG antibodies, as indicated. The results
are representative of five independent experiments. In box plot graphs, each box includes values from five different samples. All values are expressed in
arbitrary units. Differences between unphosphorylated and phosphorylated proteins were as follows. A, ##, p  0.0079 for RAF1; ###, p  0.0079 for ERK1/2 and
ADCY6. B, ##, p  0.0060 (Mann–Whitney test). C, cells deprived of IL-2 for 48 h were pretreated with a RAF1 inhibitor (10 M GW5074) or vehicle (0.1% DMSO)
() for 1 h and stimulated () or not () with 10 M 8-pCPT-2-O-Me-cAMP for 10 min and lysed. Cell lysates were used to measure cAMP accumulation. The
results show the mean  S.D. (error bars) of three independent experiments performed in duplicates. ***, p  0.001.
RAS/RAP GTPases promote glycogen phosphorylase activation
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activity. As expected, both EGF and 8-pCPT-2-O-Me-cAMP
induced strong PYG activity, and this was completely blocked
with ESI-09 (Fig. 7A). Because our data indicate that EPAC
participates in the EGFR-regulated PYG enzymatic activity, we
investigated the roles of RAS and RAP1 in this signaling path-
way. T cells were deprived of IL-2 for 48 h and were then pre-
treated with inhibitors of EPAC (10 M ESI-09), RAP1 (10 M
GGTI 298), or RAS (50 M salirasib) (40 –46) or vehicle (0.1%
DMSO) for 1 h, followed by stimulation or not with 10 ng ml1
EGFR for 10 min and measurement of PYG activity. As
expected, ESI-09 efficiently prevented EGF-induced PYG acti-
vation relative to vehicle (Fig. 7B). In addition, in the absence of
RAP1 and RAS activity (by inhibition with GGTI 298 and sali-
rasib, respectively), EGF was unable to mediate PYG activation
(Fig. 7B). Taken together, our results indicate that EGFR
requires EPAC, RAP, and RAS for PYG signaling pathway
activation.
The aforementioned results led us to investigate the EGFR-
established hierarchy between the GTPases RAP1 and RAS
with regard to PYG activation. Thus, IL-2– deprived T cells
were pretreated or not with 10 M ESI-09, 10 M GGTI 298, 50
M salirasib, or vehicle (0.1% DMSO) for 1 h, followed by stim-
ulation or not with 10 ng ml1 EGF for 10 min, and RAS acti-
vation was then measured by a pulldown assay. Control-stimu-
lated cells exhibited robust RAS activation (Fig. 8A, first panel,
lane 2), and this was completely blocked by RAS inhibition (Fig.
8A, first panel, lane 8). However, the EPAC and RAP inhibitors
(ESI-09 and GGTI 298, respectively) did not obstruct EGFR-
mediated RAS activation (Fig. 8A, first panel, lanes 4 and 6).
The detection of RAS in the whole-cell lysates validated equal
protein loading in all lanes (Fig. 8A, second panel).
To verify that RAS is upstream of RAP1 in EGFR-stimulated
T cells, IL-2– deprived cells were pretreated with 50 M salira-
sib or vehicle (0.1% DMSO) for 1 h, followed by stimulation or
not with 10 ng ml1 EGF for 10 min, and RAP1 activation was
then measured by a pulldown assay. Control-stimulated cells
exhibited robust RAP1 activation (Fig. 8B, top panel, lane 2),
which was completely blocked by salirasib (Fig. 8B, top panel,
lane 4). The detection of RAP1 in the whole-cell lysates vali-
dated equal protein loading in all lanes (Fig. 8B, second panel).
Overall, our results indicate that RAS contributes to regulate
EGFR-induced PYG activation via RAP1.
RAS signaling has been reported to be essential for EPAC2 to
activate RAP1 in a temporally and spatially controlled manner
(27). To elucidate the RAS-dependent pathway that regulates
RAP1 through EPAC, we used a combination of pharmacolog-
ical and genetic approaches to establish the possible functional
interaction between the RAS and EPAC–RAP1 pathways. We
speculated that if this interaction plays an important role in cell
signaling, blockade of EPAC activity would have a direct impact
on the activation of the RAP1 pathway. Thus, T cells were
deprived of IL-2 for 24 h and were then transfected with a con-
stitutively active form of H-RAS (pSG5-HA-H-RASG12V). After
24 h, cells were pretreated with 10 M ESI-09 or vehicle (0.1%
DMSO) for 1 h, followed by stimulation or not with 10 ng ml1
EGF for 10 min, and RAP1 activation was subsequently mea-
sured by a pulldown assay. H-RASG12V overexpression induced
substantial RAP1 activation, which was not further increased
by EGF stimulation (Fig. 9A, top panel, lanes 1 and 2). By con-
trast, overexpression of H-RASG12V in the presence of the
EPAC inhibitor ESI-09 blocked RAP1 activation, even in EGF-
stimulated cells (Fig. 9A, top panel, lanes 3 and 4). Western
blotting of RAP1 and pSG5-HA-H-RASG12V in whole-cell
lysates validated equal loading of proteins (Fig. 9A, second and
third panels).
Similar results were obtained when PYG activity was mea-
sured, with EGF maximally stimulating PYG activity in both
empty vector– and H-RASG12V–transfected cells (Fig. 9B).
H-RASG12V overexpression without EGF stimulation also in-
duced maximal PYG activity, equivalent to that stimulated by
Figure 4. Epidermal growth factor receptor activation requires RAF1 and adenylyl cyclase to induce glycogen phosphorylase activation. A, cells
deprived of IL-2 for 48 h were unstimulated () or stimulated () with 10 ng ml1 EGF, 50 g ml1 FGF, 20 ng ml1 PDGF, or 10 ng ml1 VEGF at 37 °C for 10
min and lysed. Cell lysates were used to measure glycogen phosphorylase (PYG) activity. The results presented as histograms show the mean  S.D. (error bars)
of three independent experiments performed in triplicates ***, p  0.001. B, cells deprived of IL-2 for 48 h were pretreated with an adenylyl cyclase inhibitor (10
M MDL12330A), RAF1 inhibitor (10 M GW5074), or vehicle (0.1% DMSO) () for 1 h and stimulated () or not () with 10 ng ml1 EGF and 500 units ml1 IL-2
for 10 min and lysed. Cell lysates were used to measure PYG activity. The results show the mean  S.D. of three independent experiments performed in
triplicates. ****, p  0.0001. C, cells deprived of IL-2 for 48 h were pretreated with 10 M GW2974 (EGFR inhibitor), 10 M H-89, 10 M Rp-cAMPS (PKA inhibitors),
or vehicle (0.1% DMSO) () and stimulated () or not with 10 ng ml1 EGF at 37 °C for 10 min and lysed. Cell lysates were used to measure PYG activity. The
results show the mean  S.D. of three independent experiments performed in triplicates. ***, p  0.001.
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Figure 5. Epidermal growth factor receptor controls glycogen phosphorylase activity through RAP1–RAF1–adenylyl cyclase 6 signaling pathway. A,
cells deprived of IL-2 for 48 h were pretreated with 10 M GW2974 or vehicle (0.1% DMSO) () and stimulated or not with 10 ng ml1 EGF for 10 min and lysed.
Cell lysates were used to perform a RAP1 pulldown assay. Precipitated active RAP1 (RAP1-GTP) and total RAP1, phospho-RAF1, phospho-ERK1/2, and -tubulin
from cell lysates were analyzed by Western blotting using the indicated specific antibodies. Results are representative of five independent experiments. B, T
cells deprived of IL-2 for 24 h were transfected with EGFP (esiRNA) or ADCY6 (esiRNA). At 24 h post-transfection, the cells were stimulated () or not () with 10
ng ml1 EGF for 10 min and lysed. Cell lysates were used to perform a RAP1 pulldown assay. Precipitated active RAP1 (RAP1-GTP) and total RAP1 were analyzed
by Western blotting using a specific anti-RAP1 antibody. The expression levels of endogenous ADCY6 were visualized using an anti-ADCY6 antibody and
protein load was analyzed with an anti--tubulin antibody, as indicated. The results shown are representative of five (A) and three (B) independent experi-
ments. In box plot graphs, each box includes values from five (A) or three (B) different samples. All values are expressed in arbitrary units. Differences between
different treatments were as follows. ##, p  0.0001 (RAP1); ###, p  0.05 (phospho-RAF1); ###, p  0.0079 (phospho-ERK1/2); ###, p  0.0022 (B); Mann–
Whitney test.
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EGF. By contrast, PYG activity was completely blocked in the
presence of the EPAC inhibitor, both in the control-stimulated
cells and in the H-RASG12V-overexpressed unstimulated or
stimulated cells (Fig. 9B).
Discussion
Our study reveals a novel functional cross-talk between the
small GTPase RAS and PYG guided by EGFR. This cross-talk is
grounded on the involvement of the EPAC–RAP proteins situ-
ated between RAS and PYG in the signaling cascade. To the best
of our knowledge, this is the first demonstration of PYG canon-
ical activation produced in a G protein– coupled receptor–in-
dependent manner. This novel signal transduction pathway
provides a molecular hierarchy in which RAS governs RAP acti-
vation, with an unusual relationship existing between these two
members of the same family of small GTPases, the RAS family.
Human Kit 225 T cells express IL-2R constitutively and rely
exclusively on IL-2 for cellular proliferation (34). These cells are
efficiently synchronized in G0/G1 via IL-2 deprivation for 48 h,
a feature that is advantageous for IL-2–mediated signaling
studies. We previously showed that IL-2 stimulates activation
of RAC1 and, in its active configuration, this small GTPase
binds to PYGM and modulates PYGM enzymatic activity, lead-
ing to T-cell migration and proliferation in an ADCY-indepen-
dent manner (3–5). This molecular mechanism is completely
different from that described for the canonical cAMP–PKA–
phosphorylase kinase–PYG pathway (3). Indeed, T cells can
also activate PYG by the canonical pathway, as previously
shown by us using forskolin, a classical ADCY activator (3).
Kit 225 T cells thus provide an opportunity to decipher the
involvement of other signaling pathways controlled by
ADCY that involve canonical PYG pathway activation. In
agreement with the results reported by Beazely et al. (37), in
which RAF1 was shown to phosphorylate ADCY6, we show
here that ADCY6 serine phosphorylation and PYG activa-
tion are EPAC–RAF1-dependent, a result that was further
strengthened with experiments using pharmacological treat-
ment and ADCY6 knockdown.
The functional specificity of intracellular signaling cascades
depends largely on the cellular system, intracellular localization
of the transducer molecules, and, ultimately, on the type of
stimulus. Regarding the lymphoid system, it is well-established
that tyrosine kinase–linked receptors, such as T-cell antigen
receptor (18, 19), B-cell receptor (20, 21), and IL-2R (3), actively
regulate immune response. Conversely, a receptor with intrin-
sic tyrosine kinase activity, EGFR, which is ubiquitously ex-
pressed, was traditionally considered to be absent from the
hematopoietic cell lineage. However, it was recently shown that
EGFR is expressed in both T helper-2 (32) and CD4 (33) cells. In
this context, the Kit 225 T cells used here also respond strongly
to EGFR activation, leading to PYG activation.
The EGFR signaling pathway induces a complex cascade of
phosphorylation and activation events that govern several bio-
logical processes in mammalian cells, such as growth regula-
tion, survival, proliferation, and differentiation (47–49). Active
EGFR recruits the GRB2–SOS1 complex to the plasma mem-
brane, where it drives rapid and transient activation of RAS. In
its active configuration, RAS interacts with its downstream
effector molecules through RAS-binding domains that can be
found in the majority of RAS effectors. The first and best-char-
acterized effector molecule of RAS is the serine threonine
Figure 6. Epidermal growth factor receptor requires adenylyl cyclase 6 expression to induce glycogen phosphorylase activation. A and B, T cells
deprived of IL-2 for 24 h were transfected with EGFP (esiRNA) or ADCY6 (esiRNA). At 24 h post-transfection, the cells were stimulated () or not () with 10 ng
ml1 EGF for 10 min and lysed. Cell extracts were used to measure glycogen phosphorylase activity (A) and cAMP generation (B). Protein expression levels were
analyzed by Western blotting using specific anti-ADCY6 and anti--tubulin antibodies. The results show the mean  S.D. (error bars) of three and independent
experiments performed in triplicates (A) and duplicates (B). ***, p  0.001.
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kinase RAF1 (23, 49). The RAS-RAF1 activated complex is by
far the most important regulator of the mitogen-activated pro-
tein kinase (MAPK) pathway, a key signaling cascade in medi-
ating the biological response of EGFR (47–49). This canonical
signaling network regulated by RAS is not, however, unique. In
fact, another small GTPase of the RAS family, RAP1, can also
regulate the MAPK pathway through RAF1 (50 –52). This sce-
nario raises the possibility of an EGFR-mediated ADCY6/PYG
pathway activation through RAS–RAF1 and/or RAP1–RAF1
complexes. Our findings not only reveal that the signaling
through RAF1 to activate PYG originates exclusively from
RAP, but also corroborate that RAS controls upstream RAP1
signaling.
Whereas RAF1 is the best characterized effector molecule
linked to RAS, there are other RAS effector molecules involved
in cell signaling, such as the GEFs TIAM1 (25), TIAM2, (26),
and EPAC2 (27). Although they are all considered RAS effector
molecules, TIAM1 and TIAM2 differ from EPAC2 in their
interaction with RAC1 (25), with the latter interacting with
RAP1 (27). Moreover, the active RAS form (RAS-GTP) only
interacts specifically with EPAC2 (not with EPAC1) to activate
RAP1 (27). The findings presented here point in the same
direction, as pharmacological inhibition of EPAC in consti-
tutively active H-RAS (RASG12V)-overexpressing T cells not
only blocked EGFR- and RAS-mediated RAP1 activation, but
also inhibited PYG activation.
In conclusion, our results provide insight into the molecular
mechanisms through which EGFR stimulates RAP1 activation
in T cells. We have identified EPAC2 as the GEF that specifi-
cally activates RAP1 and consequently regulates ADCY6/PYG
activation, as well as the molecular mechanism through which
EPAC2 activates the RAP1/PYG pathway. Regulation of this
novel metabolic pathway requires the involvement of the
GTPase RAS upstream of EPAC2/RAP1 and of RAP1-depen-
dent RAF1 activity (Fig. 10). The specific role of this new unex-
pected signaling pathway in T-cell physiology is still unknown.
There is controversy over the role of ADCY and its down-
stream signaling pathways in lymphocyte biology. Beckner and
Farrar (53, 54) have suggested that an inverse relationship exists
between ADCY activity and lymphocyte proliferation. In this
regard, our findings indicate that, depending on the stimulus
(i.e. IL-2 or EGF), PYG can be activated in an ADCY-dependent
or -independent manner. Furthermore, EGFR signaling through
the ADCY6/PYG pathway could be a mechanism to deactivate
IL-2 receptors in T cells and return them to their inactive state.
Future studies should address the functional importance of this
signaling cascade in the control of an efficient immune response.
Experimental procedures
Reagents
The following reagents were from Sigma-Aldrich: ADCY
activator (forskolin), DMSO, EPAC activator (8-pCPT-2-
O-Me-cAMP), PKA inhibitors (H-89 dihydrochloride and
Rp-cAMPS triethylammonium salt), RAS inhibitor (S-farnesyl-
thiosalicylic acid, salirasib), RAP inhibitor (GGTI 298 trifluoroac-
etate salt hydrate), EPAC inhibitor (3-[5-(tert-butyl)isoxazol-
3-yl]-2-[2-(3-chlorophenyl) hydrazono]-3-oxopropanenitrile,
ESI-09), RAF1 kinase inhibitor (3-(3,5-dibromo-4-hydroxy-
benzylidene)-5-iodo-1,3-dihydro-indol-2-one, GW5074), EGFR
inhibitor (N4-(1-benzyl-1H-indazol-5-yl)-N6,N6-dimethyl-pyrido-
[3,4-d]pyrimidine-4,6-diamine, GW2974), ADCY inhibitor
(MDL12330A hydrochloride), MISSION esiRNA targeting
EGFP (reference EHUEGFP) (EGFP was used as a negative
transfection control because it was lacking in our cellular
system), MISSION esiRNA targeting human ADCY6 (refer-
ence EHU08099-1), and cAMP BiotrakTM EIA (GERPN2251).
Mouse monoclonal anti-HA and anti-FLAG antibodies were
Figure 7. Epidermal growth factor receptor requires exchange proteins
activated by cAMP (EPAC) and RAS to induce glycogen phosphorylase
activation. T cells deprived of IL-2 for 48 h were pretreated with 10 M ESI-09
() or vehicle (0.1% DMSO) () (A), with 10 M ESI-09, 10 M GGTI298, 50 M
salirasib (), or vehicle (0.1% DMSO) () (B) for 1 h and stimulated () or not
() with 10 M 8-pCPT-2-O-Me-cAMP and 10 ng/ml1 EGF for 10 min and
lysed. Cell extracts were used to measure glycogen phosphorylase activity.
The results show the mean  S.D. (error bars) of three (A) and seven (B) inde-
pendent experiments performed in triplicates. ***, p  0.001.
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obtained from Covance (Princeton, NJ), and mouse mono-
clonal anti-phosphoserine clone PSR-45, polyclonal anti-
ADCY6, and anti--tubulin antibodies and mouse monoclo-
nal anti-RAS clone RAS10 antibody were obtained from
Millipore (Burlington, MA). Anti-RAP1 sc:65 antibody was
obtained from Santa Cruz Biotechnology, Inc. (Dallas, TX),
and rabbit monoclonal anti-ERK1/2, anti-phospho-ERK1/2,
anti-phospho-RAF-1, and anti-RAF-1 were obtained from Cell
Signaling Technology (Danvers, MA). The enhanced chemilumi-
nescence (ECL) reagent was obtained from GE Healthcare (Little
Chalfont, UK). Recombinant human EGF, FGF, PDGF, and VEGF
were obtained from Biovision (Milpitas, CA). IL-2 was provided by
the National Institutes of Health AIDS Reagent Program (Ger-
mantown, MD).
Cell culture and DNA/esiRNA transfections
Kit 225 T cells were cultured with 16 units ml1 of recombi-
nant human IL-2 (34). For transient transfections, cells were
cultured in complete Roswell Park Memorial Institute (RPMI)
1640 medium in the absence of IL-2 for 24 h. Thereafter, 2 
107 cells were washed, resuspended in 200 l of serum-free
medium, and placed in an electroporation cuvette (0.4 mm;
Sigma-Aldrich) containing 10 –20 g of different plasmids or
15 ng of esiRNAs, as indicated in the figures. Electroporation
was performed in a Gene Pulser Xcell Electroporator (Bio-Rad)
at 260 V and 950 microfarads (3). The cuvette contents were
then transferred into 10 ml of complete RPMI 1640 medium
and cultured without IL-2 for an additional 24 h.
Agonists and inhibitors
T cells were maintained without IL-2 for 48 h and subse-
quently treated with different stimuli: 500 units ml1 IL-2, 10
M forskolin, 10 M 8-pCPT-2-O-Me-cAMP, 10 ng ml1
VEGF, 50 g ml1 FGF, 10 ng ml1 EGF, or 20 ng ml1 PDGF
at 37 °C. In some experiments, cells were pretreated with the
following inhibitors for 1 h prior to the stimulation: 10 M ESI-
09, 10 M GGTI 298, 10 M GW2974, 10 M GW5074, 10 M
H-89, 10 M Rp-cAPMS, 10 M MDL 123300A, or 50 M sali-
rasib (Table 1).
Measurement of cAMP generation
Intracellular cAMP accumulation was quantified using an
enzyme immunoassay system (cAMP BiotrakTM EIA) from
Sigma-Aldrich. Briefly, using a centrifugal microplate adapter,
cells were centrifuged at 1000 –1500  g for 3 min, and the
pellet was resuspended in 200 l of lysis buffer (0.05 M acetate
buffer, pH 5.8, containing 0.02% BSA and 0.25% dodecyltri-
methylammonium bromide). Lysates were used in the EIA fol-
lowing the manufacturer’s recommendations. Finally, cAMP
was quantified at 450 nm in a spectrophotometer SynergyTM
HT from Bio-Tek. The data were collected using KC4 data
reduction software).
Measurement of glycogen phosphorylase activity
PYG activity was assayed as described previously (55, 56),
with some modifications. Briefly, cells were washed twice with
cold PBS and resuspended in 500 l of TES buffer (20 mM Tris,
Figure 8. Epidermal growth factor receptor requires RAS active form to mediate RAP1 activation. T cells deprived of IL-2 for 48 h were pretreated with 10
M ESI-09 () or 10 M GGTI298 (A) or with 50 M salirasib or vehicle (0.1% DMSO) () (A and B) for 1 h and stimulated () or not () with 10 ng/ml1 EGF for
10 min and lysed. Cell extracts were used to measure RAS (A) and RAP1 (B) activation assayed by a pulldown assay. The precipitated active RAS and RAP1
(RAS-GTP and RAP1-GTP) and the total RAS and RAP1 from the cell lysates were analyzed by Western blotting using specific anti-RAS and anti-RAP1 antibodies.
Immunoblots are representative of four independent experiments. In box plot graphs, each box includes values from four different samples. All values are
expressed in arbitrary units. Differences between different treatments were p  0.0001 in all cases (###) (Mann–Whitney test).
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pH 7.4, 1 mM EDTA, 225 mM sucrose, 2.5 mM DTT, 0.1 mM
PMSF, 1 g ml1 leupeptin, and 1 g ml1 aprotinin). Samples
were sonicated and centrifuged at 13,500 rpm for 10 min at
4 °C. To measure PYG activity, 100 g of total protein (1 g/l)
was used in 200 l of assay buffer (50 mM K2H2PO4, pH 7.5, 10
mM MgCl2, 5 mM EDTA, pH 8, 0.5 mM NADP, 1.5 units ml1
glucose-6-phosphate dehydrogenase, 1 unit ml1 phosphoglu-
comutase, and 0.1 mg ml1 glycogen (all from Sigma-Aldrich).
Assay buffer (100 l) containing 50 l of TES without NADP,
glycogen, phosphoglucomutase, and glucose-6-phosphate de-
hydrogenase was added to 100 g of total protein (1 g/l) as a
blank control. A metabolic activity assay was carried out by
incubating the mixture at 37 °C for 20 min. The reaction was
stopped by placing the samples on ice. Sample absorbance was
detected at 340 nm with a spectrophotometer (Ultrospec 3100
pro, Amersham Biosciences). The amount of NADPH formed
Figure 9. Epidermal growth factor receptor signaling involves RAS–EPAC–RAP pathway to activate glycogen phosphorylase. T cells deprived of IL-2 for
24 h were transfected with pSG5-HA-H-RASG12V (A) or pSG5-HA-H-RASG12V and pSG5-HA (B). At 24 h post-transfection, the cells were pretreated with 10 M
ESI-09 or vehicle (0.1% DMSO) () and stimulated () or not () with 10 ng ml1 EGF for 10 min and lysed. A, cell lysates were used to measure RAP1 activation
by a pulldown assay. The precipitated active RAP1 (RAP1-GTP) and the total RAP1 from the cell lysates were analyzed by Western blotting using a specific
anti-RAP1 antibody. The expression levels of HA-H-RASG12V and tubulin were visualized using anti-HA and anti--tubulin antibodies, as indicated. The results
shown are representative of four independent experiments. In the box plot graph, each box includes values from four different samples. All values are
expressed in arbitrary units. Differences between different treatments were p  0.0001 in all cases (##) (Mann–Whitney test). B, cell extracts were used to
measure glycogen phosphorylase activity. Protein expression levels were analyzed by Western blotting using specific anti-HA and anti--tubulin antibodies.
The results show the mean  S.D. (error bars) of four independent experiments performed in triplicates. ***, p  0.001.
RAS/RAP GTPases promote glycogen phosphorylase activation
J. Biol. Chem. (2019) 294(12) 4345–4358 4355











was determined against a standard curve of known NADPH
concentrations (Sigma-Aldrich).
RAP1 and RAS activation assay
RAP1 and RAS pulldown assays were performed using a GST
fusion recombinant protein containing the RAP1-binding
domain of Ral guanine nucleotide dissociation stimulator (Ral-
GDS) (57). Cells maintained in the absence of IL-2 for 48 h were
transfected with the indicated constructs or pretreated with
specific inhibitors and stimulated with EGF as indicated and
finally lysed in 600 l of lysis buffer (10 mM Tris, pH 7.6, 150 mM
NaCl, 1% IGEPAL-360, 10 mM MgCl2, 1 mM PMSF, 10 g/ml
aprotinin, 10 g/ml leupeptin) (58). Cell lysates were centri-
fuged at 13,500 rpm for 10 min at 4 °C, and 500 g of protein (1
g/l) from the soluble fraction was incubated for 1 h at 4 °C
with 50 g of GST-RBD of RalGDS fusion protein. Precipitated
proteins were eluted from beads using 2 loading buffer (12
mM Tris, pH 6.8, 5% glycerol, 0.4% SDS, 140 mM 2-mercapto-
ethanol, and 0.02% bromphenol blue), separated by SDS-PAGE,
and analyzed by Western blotting with specific monoclonal
antibodies. Immunoreactive bands were visualized using the
ECL reagent. Band intensities were imaged using the Molecular
Imager ChemiDocTM XRS SystemImaging Systems with
Image LabTM software from Bio-Rad and analyzed with Fiji
software.
Immunoprecipitation assay
T cells were transfected with pMT2-FLAG-ADCY6. Trans-
fected cells were pretreated or not with GW5074 for 1 h, stim-
ulated or not with 8-pCPT-2-O-Me-cAMP for 10 min, and
lysed in radioimmune precipitation assay buffer (50 mM Tris,
pH 7,4, 150 mM NaCl, 1% IGEPAL-360, 0.25% sodium deoxy-
cholate, 1 mM EDTA, 1 mM PMSF, 1 mM Na3VO4, 1 mM NaF, 1
g ml1 aprotinin, and 1 g ml1 leupeptin). Ectopic FLAG-
ADCY6 was immunoprecipitated at 4 °C for 2 h using an anti-
FLAG antibody. Immune complexes were recovered using
Gamma Bind Plus Sepharose beads (GE Healthcare), washed,
eluted from beads, resolved electrophoretically by SDS-PAGE,
and analyzed by Western blotting with anti-phosphoserine or
anti-FLAG antibodies. Immunoreactive bands were visualized
as above.
Statistical analysis
Student’s t test for paired data was used for all comparisons
with the level of significance set at p  0.001 (***), with the
exception of Fig. 4B, in which experimental groups were com-
pared using one-way ANOVA (grouped analysis) (****, p 
0.0001). The Mann–Whitney nonparametric test for densito-
metric Western blotting was used for all of the box plot analyses
with the level of significance set at p  0.05. Box plots represent
Figure 10. Proposed model of glycogen phosphorylase regulation by epidermal growth factor receptor in human Kit 225 T cells. EGFR activation leads
to the activation of the canonical RAS MAPK pathway through the GRB2–SOS complex. The results presented here document an additional signaling pathway
also stimulated by EGF, which is RAS-dependent and MAPK-independent. This new signaling cascade outlines a novel regulation of the ADCY6/PKA/PK/PYG
canonical pathway by a receptor with intrinsic tyrosine kinase activity (EGFR), which involves the RAS–EPAC2–RAP1–RAF1 pathway.
Table 1
List of inhibitors used in this study and their targets
Name/
abbreviation Chemical name Concentration Targets References
M
ESI-09 -[2-(3-Chlorophenyl)hydrazinylidene]-5-(1,1-dimethylethyl)-b-oxo-3-isoxazolepropanenitrile 10 EPAC proteins 40, 41
GGTI 298 N-[[4-(Imidazol-4-yl)methylamino]-2-(1-naphthyl)benzoyl]leucine trifluoroacetate salt 10 RAP proteins 40, 41
GW 2974 N4-(1-Benzyl-1H-indazol-5-yl)-N6,N6-dimethyl-pyrido-[3,4-d]-pyrimidine-4,6-diamine 10 EGFR 39
GW 5074 3-(3,5-Dibromo-4-hydroxybenzylidene)-5-iodo-1,3-dihydro-indol-2-one 10 RAF1 kinase 38
H-89 N-[2-(p-Bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide dihydrochloride 10 PKA 3
RP-CAMPS (R)-Adenosine, cyclic-3,5-(hydrogen phosphorothioate) triethylammonium salt 10 PKA 57
MDL 123300A cis-N-(2-Phenylcyclopentyl)-azacyclotridec-1-en-2-amine hydrochloride 10 ADCY 36
Salirasib 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid, FTS,
farnesylthiosalicylic acid, S-farnesylthiosalicylic acid
50 RAS proteins 44
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mean and 25th to 75th percentile, and whiskers represent min-
imum and maximum values. The presentation of the data is a
combination of box plots and dot plots.
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